BioLife Solutions

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioLife Solutions reports record revenue and projects strong growth

BioLife Solutions delivered strong financial performance in Q4 2022, with record revenue and growth across key revenue platforms.
Despite challenges in operating expenses and gross margin, the company remains optimistic about future growth and profitability.
By focusing on high-margin revenues, supply chain enhancements, and allogeneic therapies, BioLife is strategically positioned for long-term success.

BioLife Solutions reports revenue growth and strategic business evaluation

BioLife Solutions reported solid Q1 2023 performance with revenue growth and improved gross margin, despite short-term EBITDA challenges.
The company is strategically evaluating underperforming businesses while focusing on high-margin recurring revenue streams for future growth.
CEO's balanced approach of maintaining strengths and exploring new projects signals a commitment to sustainable profitability and innovation.
BioLife's emphasis on efficiency and strategic planning positions it well for navigating market uncertainties and driving long-term success.

BioLife Solutions reports Q2 revenue decline, focuses on strategic growth

BioLife Solutions navigated challenges in Q2 2023 with a strategic focus on higher-margin streams and a strong pipeline for growth.
Despite a decrease in revenue and challenges in key markets, the company's divestiture plans and revenue guidance reflect confidence in future performance.
Analysts' concerns about capacity constraints and operational challenges highlight areas for improvement and strategic focus for BioLife Solutions.

BioLife Solutions faces revenue decline in Q3 but eyes market growth

BioLife Solutions navigated challenges in Q3 2023 with a decline in revenue and negative adjusted EBITDA, but remains optimistic about its market position and potential for revenue recovery. Strategic divestiture plans and a focus on core products aim to drive profitability and growth.

BioLife Solutions reports 11% revenue decrease in 2023

BioLife Solutions navigated revenue challenges in 2023, with a focus on higher margin revenue streams and operational efficiency.
Despite revenue declines, the company remains optimistic about future growth opportunities in the cell processing sector.
Proactive supply chain management and a diversified supplier base position BioLife well to mitigate risks and ensure operational continuity.
Strategic plans to divest underperforming product lines and optimize operations indicate a path towards improved financial performance.

BioLife Solutions excels in Q3, shifts focus to high-margin CGT tools

BioLife Solutions demonstrated robust performance in Q3 2024, driven by strong revenue growth and strategic divestment decisions.
The company's focus on becoming a pure-play CGT tools provider and emphasis on high-margin products signal a clear strategic direction.
While facing challenges in transitioning its business model, BioLife is well-equipped to capitalize on opportunities in the growing biopreservation market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Q2 2020 was a stellar quarter for BLFS in terms of revenue generation and new customer onboarding.

BioLife Solutions: High Volatility And Growth

It's a classic vertical integration move.

BioLife Solutions to Buy SciSafe in $30 Million Deal

BOTHELL, Wash., Aug. 25, 2020 /PRNewswire/ -- BioLife Solutions, Inc.

BioLife Solutions Named one of the Top 100 Companies in Washington State

Biolife Solutions, Inc. (BLFS) CEO Michael Rice on Q2 2020 Results - Earnings Call Transcript

BOTHELL, Wash., Aug. 6, 2020 /PRNewswire/ -- BioLife Solutions, Inc.

BioLife Solutions Announces Second Quarter 2020 Financial Results

BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy BioLife (BLFS) Ahead of Earnings?

BOTHELL, Wash., July 30, 2020 /PRNewswire/ -- BioLife Solutions, Inc.

BioLife Solutions to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020

BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of...

BioLife Solutions Announces Closing of $86 Million Public Offering of Common Stock

BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: BioLife Solutions

BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

BioLife (BLFS) Catches Eye: Stock Jumps 12.1%

It doesn't look like the COVID-19 pandemic had much effect on sales of the company's bioproduction products for cell and gene therapies.

Here's Why BioLife Solutions Jumped Higher Today

BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of...

BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock

BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced estimated preliminary revenue for the second...

BioLife Solutions Announces $9.6 Million to $9.8 Million in Preliminary Revenue for Q2 2020

BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the...

BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales

The company experienced a 50% increase in its media revenues, although a considerable part of that is probably inflated by safety inventory building customers.

Solid Quarter For BioLife, But Dilution Is A Little Concerning

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2020 Results - Earnings Call Transcript

BOTHELL, Wash., May 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three months ended...

BioLife Solutions Announces First Quarter 2020 Financial Results

BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for BioLife Solutions (BLFS)

BioLife Will Suffer From Cancellations Of Trials

BioLife Solutions' (BLFS) CEO Mike Rice on Q4 2019 Results - Earnings Call Transcript

BioLife Solutions shares opened higher before moving sharply lower Thursday despite a higher analyst price target.

Analysts Back a Turnaround at BioLife Solutions

BioLife's Disappointing Quarter Masks A Much Better Future

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q3 2019 Results - Earnings Call Transcript

Biolife Solutions Digesting Big Gains; More To Follow

The shares of BioLife have sold off last month, and those of competitor CryoPort much more, closing what we thought was an irrational valuation gap.

News for BioLife Solutions Stock (BLFS)